SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001144204-18-054229
Filing Date
2018-10-17
Accepted
2018-10-17 16:31:03
Documents
6
Period of Report
2018-12-13
Effectiveness Date
2018-10-17

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT tv504383-def14a.htm DEF 14A 137259
2 GRAPHIC lg_protalix.jpg GRAPHIC 25457
3 GRAPHIC sg_moshe-manor.jpg GRAPHIC 13218
4 GRAPHIC sig_yossi-maimon.jpg GRAPHIC 9221
5 GRAPHIC tv504256_pc1.jpg GRAPHIC 399420
6 GRAPHIC tv504256_pc2.jpg GRAPHIC 541737
  Complete submission text file 0001144204-18-054229.txt   1500485
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 181126668
SIC: 2836 Biological Products, (No Diagnostic Substances)